001374406 000__ 02516nam\\2200493\i\4500
001374406 001__ 1374406
001374406 003__ OCoLC
001374406 005__ 20210929003158.0
001374406 007__ he\bmb024bbca
001374406 008__ 200424s2018\\\\dcua\\\\bb\\\f000\0\eng\c
001374406 035__ $$a(OCoLC)1151883907
001374406 040__ $$aGPO$$beng$$erda$$cGPO$$dISE
001374406 042__ $$apcc
001374406 043__ $$an-us---
001374406 049__ $$aISEA
001374406 074__ $$a1043-B (MF)
001374406 0860_ $$aY 4.L 11/4:S.HRG.114-805
001374406 1101_ $$aUnited States.$$bCongress.$$bSenate.$$bCommittee on Health, Education, Labor, and Pensions.$$bSubcommittee on Children and Families,$$eauthor.
001374406 24510 $$aEpiPen price increases :$$bhow regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY).
001374406 24630 $$aHow regulatory barriers inhibit pharmaceutical competition
001374406 264_1 $$aWashington :$$bU.S. Government Publishing Office,$$c2018.
001374406 300__ $$aiii, 43 pages :$$billustrations ;$$c24 cm.
001374406 336__ $$atext$$btxt$$2rdacontent
001374406 337__ $$amicroform$$bh$$2rdamedia
001374406 338__ $$amicrofiche$$bhe$$2rdacarrier
001374406 4901_ $$aS. hrg. ;$$v114-805
001374406 500__ $$aShipping list no.: 2019-0162-M.
001374406 504__ $$aIncludes bibliographical references.
001374406 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cU.S. Government Printing Office,$$d[2018]$$e1 microfiche : negative.
001374406 650_0 $$aPrescription pricing$$zUnited States.
001374406 650_0 $$aDrugs$$xLaw and legislation$$zUnited States.
001374406 650_0 $$aPharmaceutical industry$$zUnited States.
001374406 650_0 $$aCompetition$$zUnited States.
001374406 650_0 $$aDrug delivery devices$$xPrices$$zUnited States.
001374406 650_7 $$aCompetition.$$2fast$$0(OCoLC)fst00871464
001374406 650_7 $$aDrugs$$xLaw and legislation.$$2fast$$0(OCoLC)fst00898830
001374406 650_7 $$aPharmaceutical industry.$$2fast$$0(OCoLC)fst01060129
001374406 650_7 $$aPrescription pricing.$$2fast$$0(OCoLC)fst01075656
001374406 651_7 $$aUnited States.$$2fast$$0(OCoLC)fst01204155
001374406 77608 $$iPrint version:$$aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.$$tEpiPen price increases$$w(DLC)  2018439951$$w(OCoLC)1078409593
001374406 77608 $$iOnline version:$$aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.$$tEpiPen price increases$$w(OCoLC)1078951640
001374406 8101_ $$aUnited States.$$bCongress.$$bSenate.$$tS. hrg. ;$$v114-805.
001374406 852__ $$bdfich
001374406 852__ $$bedoc$$hY 4.L 11/4:S.HRG.114-805
001374406 85640 $$uhttps://purl.fdlp.gov/GPO/gpo113215
001374406 909CO $$ooai:library.usi.edu:1374406$$pGLOBAL_SET
001374406 980__ $$aBIB
001374406 980__ $$aEGOV
001374406 982__ $$aGovernment E-Resource
001374406 983__ $$aOnline
001374406 994__ $$aC0$$bISE